Synthaverse Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Mieczyslaw Starkowicz

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.8yrs
CEO ownership0.1%
Management average tenureno data
Board average tenure2.8yrs

Recent management updates

Recent updates

Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Apr 20
Optimistic Investors Push Synthaverse S.A. (WSE:SVE) Shares Up 32% But Growth Is Lacking

Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

Apr 18
Why Synthaverse's (WSE:SVE) Soft Earnings Are Just The Beginning Of Its Problems

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

Oct 14
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Seems To Use Debt Quite Sensibly

More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

Nov 29
More Unpleasant Surprises Could Be In Store For BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Shares After Tumbling 48%

We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Nov 16
We Think You Should Be Aware Of Some Concerning Factors In BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek's (WSE:BML) Earnings

Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

May 02
Does BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Deserve A Spot On Your Watchlist?

Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

Mar 08
Is BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) A Risky Investment?

What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Jan 29
What Percentage Of BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) Shares Do Insiders Own?

Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 03
Should Weakness in BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.'s (WSE:BML) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

Dec 07
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek (WSE:BML) Takes On Some Risk With Its Use Of Debt

CEO

Mieczyslaw Starkowicz

1.8yrs

Tenure

Mr. Mieczyslaw Starkowicz serves as President of the Management Board and Chief Executive Officer at Synthaverse S.A. (formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A.) since August 202...


Board Members

NamePositionTenureCompensationOwnership
Waldemar Sierocki
Secretary of Supervisory Board & Member of Supervisory Boardno datazł24.00k6.79%
PLN 23.7m
Konrad Miterski
Member of the Supervisory Boardno datazł42.00k0.049%
PLN 172.1k
Wiktor Napióra
Vice Chairman of the Supervisory Boardno datazł40.00k7.13%
PLN 24.9m
Dariusz Kucowicz
Member of Supervisory Board16.3yrszł39.00k0.14%
PLN 495.0k
Maciej Korniluk
Member of Supervisory Board1.3yrsno datano data
Jaroslaw Blaszczak
Chairman of the Supervisory Boardno datazł113.00k1.92%
PLN 6.7m
Dirk Pamperin
Member of the Supervisory Board4.3yrszł37.00kno data
Maciej Siedlar
Member of Supervisory Board1.3yrsno data0.14%
PLN 495.9k

2.8yrs

Average Tenure

Experienced Board: SVE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.